{
  "ticker": "EXAS",
  "content": "**Report Generated:** January 25, 2026  \n**Next Refresh:** April 26, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Exact Sciences Corporation (EXAS) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.\n\nThe company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its core business revolves around non-invasive screening and precision oncology tests, all driven by a mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.\n\n## 2. Current Market Data\n\nThe current price of EXAS is 102.26 USD — it has decreased by −0.11% in the past 24 hours. Today Exact Sciences Corporation has the market capitalization of ‪19.53 B‬, it has increased by 1.04% over the last week. The market cap of Exact Sciences (EXAS) is $19.53B as of Jan 20, 2026. NASDAQ: EXAS · $ 102.48 · January 21, 2026 04:00 PM · Day High: 102.55 · Day Low: 102.25 · 52-Week High: 102.66 · 52-Week Low: 38.81\n\n## 3. Existing Products/Services\n\n### Primary Products:\n• **Cologuard & Cologuard Plus**: The Cologuard® test, a market-leading noninvasive colorectal cancer screening option FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.\n\n• **Oncotype DX Suite**: Oncotype DX®, which informs personalized treatment decisions for patients with breast cancer and includes tests for breast and colon cancers.\n\n• **OncoExTra Test**: For tumor profiling in advanced cancer patients.\n\n• **Riskguard Test**: A hereditary cancer test for assessing inherited cancer risk.\n\n## 4. Planned Products/Services/Projects\n\n### Recently Launched (2025):\n• **Cancerguard**: Cancerguard is the first multi-cancer early detection test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited. Cancerguard detects 50 cancer types, even the most aggressive – such as pancreatic, ovarian, liver, esophageal, lung and stomach – through a simple blood draw\n\n• **Oncodetect**: Oncodetect™, which identifies molecular residual disease (MRD) to help assess the risk of recurrence and guide follow-up care\n\n• **Oncoguard Liver Test**: Oncoguard Liver Test finds the most common liver cancer in people with cirrhosis or chronic hepatitis B\n\n### Pipeline Development:\nIn addition to its current products, Exact Sciences is also advancing a leading pipeline of next-generation cancer diagnostics designed to detect cancer even earlier, optimize treatment decisions and enable regular monitoring to help people stay healthy and better manage the disease.\n\n## 5. Growth Strategy\n\nThe broader vision, which drives the current portfolio expansion, is a commitment to pursuing earlier cancer detection, treatment guidance, and monitoring across multiple cancer types. The vision of 'earlier, smarter answers' is directly tied to their aggressive product pipeline, which is the engine for their 2025 financial performance.\n\nKey strategic initiatives include:\n• Expanding multi-cancer detection capabilities beyond colorectal cancer\n• Leveraging liquid biopsy technologies for blood-based testing\n• Building partnerships with healthcare systems and payers\n• International expansion efforts\n• Direct-to-consumer marketing initiatives\n\n## 6. Current and Potential Major Clients\n\n### Current Partnerships:\n• Agreement with Quest Diagnostics to enable blood collection at the company's approximately 7,000 patient access sites across the U.S., including through its patient service centers and in-office phlebotomists in provider offices, as well as mobile phlebotomy services for at-home collections\n• Partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage members nationwide beginning in August 2025. Humana, the fourth largest private insurer in the United States, has approximately 5.8 million Medicare Advantage members.\n• License agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University.\n\n### Provider Network:\nThe company's expanding global footprint, which now includes over 7,000 team members worldwide, nine R&D centers and labs, and relationships with more than 200,000 ordering providers each quarter.\n\n## 7. Financial Data & Performance\n\n### Q3 2025 Results:\nGenerated revenue of $851 million for the third quarter ended September 30, 2025, compared to $709 million for the same period of 2024. Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million\n\nOperating cash flow increased 59% year-over-year to $220 million, driving free cash flow (FCF) up 69% to a record $190 million.\n\nThe non-GAAP gross margin remains high at 71% in Q3 2025, while Adjusted EBITDA margins rose 200 basis points to 16%, with free cash flow reaching $190 million.\n\n### 2025 Guidance:\nFull-year 2025 revenue between $3.22 billion and $3.235 billion, a significant jump driven by its dual strategy of screening and precision oncology\n\n## 8. Headwinds & Tailwinds\n\n### Tailwinds:\n• **Market Leadership**: Cologuard transformed colorectal cancer screening—driving an estimated 77% of the nationwide increase in CRC screening participation from 2018 to 2023 and enabling more than 19 million screenings to date.\n• **Growing Market**: The CRC screening market is estimated to be worth about $17B and growing.\n• **Strong Cash Generation**: Record free cash flow provides funding for R&D and new product launches\n• **Abbott Acquisition**: Provides significant financial backing and expanded distribution capabilities\n\n### Headwinds:\n• **Competition**: Facing competition from liquid biopsy companies and traditional screening methods\n• **Reimbursement Challenges**: Need to secure payer coverage for new products\n• **Integration Costs**: Ongoing restructuring and integration expenses\n• **Regulatory Approval**: New products require clinical validation and regulatory clearance\n\n## 9. Market Shares\n\n### Cancer Screening/Liquid Biopsy Market:\nLeading companies include: F. Hoffmann-La Roche AG (5%), Thermo Fisher Scientific Inc (3%), Guardant Health Inc (3%), Illumina Inc (3%), Exact Sciences Corporation (2%), Natera Inc (2%)\n\n### Multi-Cancer Early Detection (MCED) Market:\nThe top five companies GRAIL, Inc. (Illumina, Inc.), Guardant Health, Exact Sciences Corporation, Freenome Holdings, and Burning Rock Biotech collectively account for 65% of the global market share\n\n### Colorectal Cancer Screening:\nIts flagship product line is Cologuard, the market leader in stool-based screening for colorectal cancer, or CRC. Cologuard has achieved dominant market share in the non-invasive colorectal cancer screening segment.\n\n## 10. Comparison to Competitors\n\n### Key Competitors:\n• **Guardant Health**: Competing in liquid biopsy and multi-cancer detection\n• **Natera**: Strong presence in liquid biopsy and molecular residual disease testing\n• **Illumina/GRAIL**: Leading in multi-cancer early detection\n• **Foundation Medicine/Roche**: Comprehensive genomic profiling\n\n### Competitive Advantages:\n• Market-leading position in colorectal cancer screening\n• Strong brand recognition and physician adoption\n• Comprehensive product portfolio spanning screening to precision oncology\n• Robust clinical validation and regulatory approvals\n\n## 11. Partnerships, Mergers and Acquisitions\n\n### Major Acquisition Announcement:\nUnder the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion from Abbott Laboratories. The closing is expected in the second quarter of 2026 and is subject to Exact Sciences' shareholder approval, as well as receipt of applicable regulatory approvals and other customary closing conditions.\n\n### Historical Acquisitions:\nIn its largest acquisition yet, announced its intention to buy Genomic Health, a genetic cancer detection company based in Redwood City, California, for $2.8 billion. This brought the Oncotype DX platform into the company's portfolio.\n\n## 12. Recent Developments\n\n### Abbott Acquisition (November 2025):\nIn November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion. The transaction was unanimously approved by both companies' boards of directors.\n\n### Product Launches (2025):\n• **Cancerguard Launch**: Multi-cancer early detection test launched in Q3 2025\n• **Cologuard Plus Expansion**: Next-generation colorectal cancer screening test with improved accuracy\n• **Oncodetect Introduction**: Molecular residual disease testing platform\n\n### Financial Performance:\nRaised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively following strong Q3 2025 results.\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n### Investment Rating: 7.8/10\n\n**Rationale:**\nThe acquisition by Abbott at $105 per share provides a clear exit price and removes much of the investment uncertainty. The current stock price trading near the acquisition price (~$102) offers limited upside but minimal downside risk given the deal's strong regulatory and financial backing.\n\n**Strengths:**\n- Market-leading position in colorectal cancer screening\n- Strong financial performance with growing revenue and improving cash generation  \n- Successful product launches expanding addressable market\n- Abbott acquisition provides premium exit at attractive valuation\n- Robust pipeline in high-growth cancer diagnostics segments\n\n**Risks:**\n- Deal completion risk (regulatory approvals, shareholder vote)\n- Limited stock price appreciation potential given acquisition cap\n- Competitive pressures in liquid biopsy market\n- Execution risk on new product launches\n\n### Fair Value Estimate: $105.00\n\nGiven the definitive agreement for Abbott to acquire Exact Sciences at $105 per common share and the transaction expected to close in Q2 2026, subject to shareholder and regulatory approvals, the fair value is effectively capped at the acquisition price. The deal represents an appropriate premium for the company's market position, growth prospects, and strategic value to Abbott's diagnostics portfolio.\n\n**Recommendation:** HOLD - The stock offers limited upside given the pending acquisition but provides a secure return through deal completion. The $105 acquisition price represents fair value for the company's current position and future prospects in the growing cancer diagnostics market.",
  "generated_date": "2026-01-25T08:06:00.085368",
  "next_refresh_date": "2026-04-26T08:06:00.085368",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.4109484,
  "tokens": {
    "input": 190,
    "output": 3948,
    "cache_creation": 74344,
    "cache_read": 241228
  },
  "tldr_summary": "Exact Sciences Corporation is a molecular diagnostics company specializing in cancer screening and early detection, offering innovative tests like Cologuard for colorectal cancer and multi-cancer screening technologies. \n\nThe company is positioned as a leader in cancer diagnostics, with a comprehensive portfolio including Cologuard, Oncotype DX, and newly launched Cancerguard, which can detect 50 cancer types through a blood draw. Exact Sciences is strategically expanding its multi-cancer detection capabilities, building healthcare partnerships, and pursuing international growth. In a significant development, Abbott Laboratories has agreed to acquire the company for $21 billion at $105 per share, expected to close in Q2 2026, which provides substantial validation of the company's market position and technology.\n\nWith strong revenue growth, a robust product pipeline, and the pending high-premium acquisition, the AI investment rating is 7.8/10, recommending a HOLD strategy with fair value estimated at $105.00 per share."
}